NGC Update Service: November 24, 2014

National Guideline Clearinghouse (NGC)

November 24, 2014


New This Week

Guideline Summaries

American Society of Clinical Oncology

National Heart, Lung, and Blood Institute (U.S.)

Announcements

NGC Spotlight

New research review added! Visit the AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program.

Health Awareness Topics - November 2014

Conference News

  • The Guidelines International Network North America (G-I-N/NA) and the Section on Evidence Based Health Care (SEBHC) of The New York Academy of Medicine are co-sponsoring the second conference on "Evidence-based Guidelines Affecting Policy, Practice and Stakeholders" March 2-3, 2015 in New York City, NY. Registration is now open.

    Conference objectives are as follows:

    • To provide a platform for constructive dialogue between stakeholders in the development, implementation and use of clinical guidelines
    • To enhance successful uptake, implementation and use of clinical guidelines through fostering ongoing collaboration between relevant stakeholders
  • The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.

U.S. Food and Drug Administration (FDA) Advisory

  • November 16, 2014: Long-term Antiplatelet Therapy: FDA is evaluating preliminary data from a clinical trial showing that treatment for 30 months with dual antiplatelet blood-thinning therapy decreased the risk of heart attacks and clot formation in stents, but there was an increased overall risk of death compared to 12 months of treatment. The clinical trial compared 30 months versus 12 months of treatment with dual antiplatelet therapy consisting of aspirin plus either clopidogrel (Plavix) or prasugrel (Effient), following implantation of drug-eluting coronary stents. FDA believes the benefits of clopidogrel (Plavix) and prasugrel (Effient) therapy continue to outweigh their potential risks when used for approved uses.

NGC's Sister Resource

Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).